PMC full text: | Published online 2023 Aug 8. doi: 10.1002/cam4.6425
|
Parameter (n=44) | Decreased tumour size relative to the median | p Value (chi‐square) | Decreased Ki‐67 level relative to the median | p Value (chi‐square) | ||
---|---|---|---|---|---|---|
Good (n) (>4.5mm) | Bad (n) (<=4.5mm) | Good (n) (>9) | Bad (n) (<=9) | |||
Menopausal status | ||||||
Premenopausal | 4 | 6 | 0.71 | 3 | 5 | 0.42 |
Postmenopausal | 18 | 16 | 16 | 10 | ||
Intrinsic subtype | ||||||
Luminal A | 10 | 10 | 1 | 13 | 15 | 0.0001 |
Luminal B | 10 | 12 | 6 | 15 | ||
Nuclear Grade | ||||||
G1 | 7 | 7 | 0.98 | 5 | 6 | 0.70 |
G2 | 10 | 11 | 11 | 7 | ||
G3 | 1 | 1 | 1 | 1 | ||
RCB class | ||||||
I | 2 | 2 | 0.54 | 2 | 2 | 0.79 |
II | 19 | 18 | 18 | 19 | ||
III | 2 | 1 | 2 | 1 | ||
PD‐L1 before NET | ||||||
PD‐L1 (−) | 19 | 20 | 1 | 17 | 14 | 0.60 |
PD‐L1 (+) | 2 | 2 | 2 | 14 | ||
PD‐L1 after NET | ||||||
PD‐L1 (−) | 16 | 16 | 1 | 14 | 10 | 1 |
PD‐L1 (+) | 5 | 6 | 5 | 4 | ||
PD‐1 before NET | ||||||
PD‐1 (+) | 18 | 15 | 0.28 | 12 | 13 | 0.17 |
PD‐1 (−) | 2 | 6 | 6 | 1 | ||
PD‐1 after NET | ||||||
PD‐1 (+) | 15 | 12 | 0.28 | 13 | 6 | 0.18 |
PD‐1 (−) | 5 | 10 | 5 | 8 | ||
CTLA‐4 before NET | ||||||
CTLA‐4 (−) | 17 | 14 | 0.31 | 15 | 8 | 0.34 |
CTLA‐4 (+) | 3 | 7 | 3 | 5 | ||
CTLA‐4 after NET | ||||||
CTLA‐4 (−) | 13 | 14 | 0.81 | 12 | 10 | 1 |
CTLA‐4 (+) | 7 | 5 | 6 | 4 | ||
TIM‐3 before NET | ||||||
TIM‐3 (−) | 8 | 6 | 0.74 | 7 | 5 | 1 |
TIM‐3 (+) | 13 | 15 | 11 | 9 | ||
TIM‐3 after NET | ||||||
TIM‐3 (−) | 9 | 8 | 1 | 7 | 4 | 0.93 |
TIM‐3 (+) | 11 | 12 | 11 | 9 | ||
LAG‐3 before NET | ||||||
LAG‐3 (−) | 12 | 7 | 0.27 | 5 | 8 | 0.23 |
LAG‐3 (+) | 9 | 13 | 12 | 6 | ||
LAG‐3 after NET | ||||||
LAG‐3 (−) | 7 | 6 | 1 | 2 | 6 | 0.09 |
LAG‐3 (+) | 14 | 15 | 16 | 8 |
Abbreviations: RCB, Residual Cancer Burden; NET, neoadjuvant endocrine therapy.
Note: Bold values denote statistical significance at the p<0.05 level.